Compare TOI & SCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOI | SCM |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | 641 | N/A |
| Industry | Medical/Nursing Services | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.4M | 267.2M |
| IPO Year | N/A | 2012 |
| Metric | TOI | SCM |
|---|---|---|
| Price | $4.10 | $9.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | $6.67 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.4M | 127.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 14.22% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | N/A |
| Revenue This Year | $30.15 | $0.33 |
| Revenue Next Year | $25.77 | N/A |
| P/E Ratio | ★ N/A | $152.83 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.02 | $8.43 |
| 52 Week High | $4.88 | $15.39 |
| Indicator | TOI | SCM |
|---|---|---|
| Relative Strength Index (RSI) | 63.16 | 34.20 |
| Support Level | $3.35 | $8.80 |
| Resistance Level | $4.15 | $9.85 |
| Average True Range (ATR) | 0.25 | 0.27 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 70.31 | 2.13 |
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.